Crescent Biopharma (CBIO) Financials: Revenue & Earnings

CBIO price $13.26 -0.01 -0.11%

Ticker
CBIO
Price
$13.26
Change
-0.01 -0.11%
Market cap ?
$492.34M
P/E ?
-1.69
Dividend yield ?
0.00%
Beta ?
1.26
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
66
Value
58
Quality
40
Growth
100

Stocklytics score rationale: value 58, quality 40, growth 100.

Financials

2016201720182019202020212022202320242025
185000001016293511597677500010000010844000

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance…

Fair value

CBIO fair value Not meaningful. Price $13.26.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare CBIO

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-0.67—357.14K
2026-07-30-0.74-0.74—357.14K
2026-04-29-0.70-0.851.00M357.14K
2026-02-26-4.01-2.2210.84M10.00M
2025-11-06-1.27-1.01—30.56M
2025-08-06-4.93-2.69——
2025-05-14-0.04-5.00——
2025-02-13-0.11-0.16——
2024-11-13-0.15-0.11——
2024-08-08-0.16-0.17——
2024-05-09-0.17-0.16——
2024-03-27-0.14-0.1510.00K—
2023-11-03-14.00-0.14—50.00K
2023-08-02-13.00-0.18—50.00K
2023-05-03-17.00-0.17——
2023-03-29-19.00-0.17——
2022-11-09-0.16-0.25—215.05K
2022-08-03-0.25-0.2875.00K417.45K
2022-04-28-0.46-0.44—757.91K
2022-03-03-0.64-0.3418.00K—
2021-11-02-0.80-0.6686.56K81.15K
2021-08-05-0.64-30.75142155
2021-05-03-28.00-0.581.06M1.19M
2021-03-02-32.00-31.40162.94K333.33K
2020-11-06-28.88-32.001.00B1.14B
2020-07-31-32.00-37.00—10.69B
2020-05-01-17.58-29.609.00M15.00M
2020-02-28-34.00-35.00——
2019-11-07-30.61-39.00——
2019-08-01-36.66-36.00——
2019-05-02-32.63-34.00——
2019-03-06-32.00-30.00——
2018-11-02-26.88-30.00——
2018-08-09-26.00-34.00——
2018-05-03-32.75-0.82—12.32K
2018-03-06-27.00-26.00——
2017-11-08-24.00-1.30—315.22K
2017-08-03-29.89-1.45—110.08K
2017-05-08-33.78-7.61—359.80K
2017-03-01-0.36-0.3450017.50K

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency Quarterly.

Safety score 43/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. Dividend history is short. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
2023-01-13$24.00——Quarterly
2022-09-21$143.00——Annual

Insider trades

DateInsiderActionSharesPriceValue
2026-09-18Brumm Joshua TSell7.84K$16.71130.96K
2026-09-18McNeill JonathanSell3.84K$16.7164.15K
2026-09-16Lynch RyanSell240$17.904.30K
2026-09-16Pinkas JanSell658$17.9011.78K
2026-09-16Im Ellie EunkyungSell623$17.9011.15K
2026-09-16Scalzo Richard WilliamSell568$17.9010.17K
2026-09-16Bispham Barbara HarlinSell620$17.9011.10K
2026-09-16Brumm Joshua TSell1.61K$17.9028.82K
2026-09-16McNeill JonathanSell731$17.9013.08K
2026-07-16Fairmount Funds Management LLCBuy853.45K$14.5012.38M
2026-07-16Fairmount Funds Management LLCBuy525.90K$0.00526
2026-06-22Lynch RyanSell465$17.998.37K
2026-06-22Pinkas JanSell1.29K$17.9923.17K
2026-06-22Scalzo Richard WilliamSell1.11K$17.9920.00K
2026-06-22Bispham Barbara HarlinSell1.22K$17.9921.91K
2026-06-22Im Ellie EunkyungSell1.22K$17.9921.93K
2026-06-22McNeill JonathanSell20.55K$17.99369.68K
2026-06-22Brumm Joshua TSell42.30K$17.99761.07K
2026-06-02Violin JonathanBuy11.05K$17.01187.96K
2026-06-02Lubner David CharlesBuy11.05K$17.01187.96K
2026-06-02Balcom AlexandraBuy11.05K$17.01187.96K
2026-06-02Moran SusanBuy11.05K$17.01187.96K
2026-06-02Fairmount Funds Management LLCBuy11.05K$17.01187.96K
2025-12-15Pinkas JanBuy70.03K$13.21925.03K
2025-12-15Pinkas JanBuy5.00K——
2025-12-15Pinkas JanBuy17.51K——
2025-12-15Doughty Christopher GrantBuy8.00K——
2025-12-15Doughty Christopher GrantBuy58.85K$13.21777.47K
2025-12-15Doughty Christopher GrantBuy14.71K——
2025-12-15Brumm Joshua TBuy10.00K——
2025-12-15Brumm Joshua TBuy45.12K——
2025-12-15Brumm Joshua TBuy180.47K$13.212.38M
2025-12-15Scalzo Richard WilliamBuy57.69K$13.21762.06K
2025-12-15Scalzo Richard WilliamBuy5.00K——
2025-12-15Scalzo Richard WilliamBuy14.42K——
2025-12-15McNeill JonathanBuy6.00K——
2025-12-15McNeill JonathanBuy19.51K——
2025-12-15McNeill JonathanBuy78.03K$13.211.03M
2025-12-15Im Ellie EunkyungBuy65.19K$13.21861.16K
2025-12-15Im Ellie EunkyungBuy5.00K——
2025-12-15Im Ellie EunkyungBuy16.30K——
2025-12-15Lynch RyanBuy33.51K$13.21442.69K
2025-12-15Lynch RyanBuy4.00K——
2025-12-15Lynch RyanBuy8.38K——
2025-12-15Bispham Barbara HarlinBuy72.19K$13.21953.56K
2025-12-15Bispham Barbara HarlinBuy6.00K——
2025-12-15Bispham Barbara HarlinBuy12.42K——
2025-12-08McNeill JonathanBuy172.84K$13.172.28M
2025-12-08Brumm Joshua TBuy345.67K$13.174.55M
2025-12-04Fairmount Funds Management LLCBuy1.36M$13.4118.24M
2025-12-04Fairmount Funds Management LLCBuy131.43K$0.00131
2025-07-16Pinkas JanBuy142.47K$13.141.87M
2025-07-07Pinkas JanOther0——
2025-06-23Moran SusanBuy9.02K$15.30138.05K
2025-06-23Fairmount Funds Management LLCBuy9.02K$15.30138.05K
2025-06-23Violin JonathanBuy9.02K$15.30138.05K
2025-06-23Balcom AlexandraBuy9.02K$15.30138.05K
2025-06-23Lubner David CharlesBuy9.02K$15.30138.05K
2025-06-13Im Ellie EunkyungOther257.82K$9.562.46M
2025-06-13Balcom AlexandraOther20.16K$6.16124.21K
2024-08-08Invus Public Equities, L.P.Sell260.87K$0.1950.01K
2024-08-07Invus Public Equities, L.P.Sell61.49K$0.1811.20K
2024-08-06Invus Public Equities, L.P.Sell55.73K$0.1810.19K
2024-08-05Invus Public Equities, L.P.Sell164.52K$0.1931.00K
2024-08-02Invus Public Equities, L.P.Sell286.20K$0.2057.35K
2024-08-01Invus Public Equities, L.P.Sell63.56K$0.2213.74K
2024-07-30Invus Public Equities, L.P.Sell756.84K$0.22167.18K
2024-07-29Invus Public Equities, L.P.Sell363.95K$0.2485.64K
2024-07-26Invus Public Equities, L.P.Sell258.33K$0.2462.44K
2024-07-25Siren, L.L.C.Sell0——
2024-06-21Rock EdwinBuy115.00K$0.2730.72K
2024-06-20Rock EdwinBuy190.00K$0.2548.11K
2024-06-18Hahn Brian M.Buy17.50K$0.254.33K
2024-05-01Koenig ScottBuy40.00K$1.6264.80K
2024-05-01Goldberg Mark AlanBuy40.00K$1.6264.80K
2024-05-01PEARSON TIMOTHY RBuy40.00K$1.6264.80K
2024-05-01King Rachel K.Buy40.00K$1.6264.80K
2024-05-01Andrews Patricia SBuy40.00K$1.6264.80K
2024-05-01Jackson Scott ThomasBuy40.00K$1.6264.80K
2024-05-01JUNIUS DANIEL MBuy40.00K$1.6264.80K
2024-03-29JUNIUS DANIEL MBuy5.21K$3.0015.63K
2024-03-29King Rachel K.Buy3.33K$3.0010.00K
2024-03-29Goldberg Mark AlanBuy4.58K$3.0013.75K
2024-01-12Johnson Bruce SBuy250.00K$3.11777.50K
2024-01-12Semerjian HaroutBuy695.00K$3.112.16M
2024-01-12Rock EdwinBuy250.00K$3.11777.50K
2024-01-12Rath ChinmayaBuy250.00K$3.11777.50K
2024-01-12Hahn Brian M.Buy250.00K$3.11777.50K
2023-12-29Andrews Patricia SBuy5.19K$2.3612.25K
2023-12-29King Rachel K.Buy4.24K$2.3610.00K
2023-12-29Goldberg Mark AlanBuy5.83K$2.3613.75K
2023-09-30Goldberg Mark AlanBuy9.17K$1.5013.75K
2023-09-30Andrews Patricia SBuy8.17K$1.5012.25K
2023-09-30King Rachel K.Buy6.67K$1.5010.00K
2023-09-22Rock EdwinBuy30.40K$1.3841.96K
2023-09-21Rock EdwinBuy35.00K$1.3848.30K
2023-06-01Koenig ScottBuy21.00K$0.6012.60K
2023-06-01Koenig ScottSell21.00K$0.6012.60K
2023-05-19King Rachel K.Buy35.00K$1.9869.30K
2023-05-19JUNIUS DANIEL MBuy35.00K$1.9869.30K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 82, holders +22 vs prior quarter. Ownership 95.52%.

HolderSharesChangeChange %Value
FMR LLC4.13M00.00%74.40M
BVF INC/IL2.75M00.00%49.48M
FAIRMOUNT FUNDS MANAGEMENT LLC2.75M00.00%49.46M
VENROCK ADVISER, LLC2.13M00.00%38.40M
LOGOS GLOBAL MANAGEMENT LP1.90M1.42M+293.78%34.20M
FCPM III SERVICES B.V.1.68M00.00%30.20M
BALYASNY ASSET MANAGEMENT L.P.1.66M152.88K+10.12%29.93M
VESTAL POINT CAPITAL, LP1.63M130.00K+8.67%29.34M
OPALEYE MANAGEMENT INC.1.32M6.74K+0.51%23.75M
BLACKROCK, INC.1.27M1.16M+998.95%22.89M
TANG CAPITAL MANAGEMENT LLC1.16M00.00%20.88M
VANGUARD CAPITAL MANAGEMENT LLC767.75K-33.64K-4.20%13.82M
MILLENNIUM MANAGEMENT LLC403.86K80.31K+24.82%7.27M
GEODE CAPITAL MANAGEMENT, LLC384.58K280.36K+269.00%6.92M
JENNISON ASSOCIATES LLC378.51K225.53K+147.43%6.81M
NEXTBIO CAPITAL MANAGEMENT LP372.86K00.00%6.71M
RTW INVESTMENTS, LP372.86K00.00%6.71M
REMEDIUM CAPITAL PARTNERS, LLC361.25K361.25KNew6.50M
STATE STREET CORP315.59K276.52K+707.81%5.68M
AMERIPRISE FINANCIAL INC302.57K302.57KNew5.45M
POINT72 ASSET MANAGEMENT, L.P.300.00K00.00%5.40M
PRICE T ROWE ASSOCIATES INC /MD/275.58K-27.97K-9.21%4.96M
MARSHALL WACE, LLP214.30K13.52K+6.73%3.86M
PERCEPTIVE ADVISORS LLC206.94K00.00%3.72M
VANGUARD PORTFOLIO MANAGEMENT LLC188.80K188.80KNew3.40M

Earnings and financials

Crescent Biopharma, Inc. (CBIO) trades at $13.26, with a market cap of $492.34M and a trailing P/E of -1.69. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
185000001016293511597677500010000010844000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Crescent Biopharma (CBIO) Financials: Revenue & Earnings

CBIO$13.26-0.01 -0.11%

$492.34M

Market Cap

-1.69

P/E

—

Forward P/E

66

Score

Price History